Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

Covington
Healthtrust
Citi
Cantor Fitzgerald
Daiichi Sankyo
Julphar

Generated: August 18, 2019

DrugPatentWatch Database Preview

Claims for Patent: 6,515,204

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for Patent: 6,515,204
Title: Corn silk gene and regulatory region
Abstract:The invention can be summarized as follows. Several silk-specific genes were isolated from corn silk. The specificity of their expression was determined by Northern analysis. A regulatory region was obtained from the silk gene, C3, and found to direct silk, and pistil, expression in transient assays and transgenic plants, in both monocot and dicot plants. The regulatory region of a silk gene may be used to drive the expression of a gene of interest within pistil or silk-tissues for a range of utilities including pathogen resistance or female sterility.
Inventor(s): Ouellet; Therese (Nepean, CA), Singh; Jas (Nepean, CA), Tao; Titus (Ottawa, CA), Simmonds; John (Nepean, CA)
Assignee: Her Majesty the Queen in right of Canada, as represented by The Minister of Agriculture and Agri-Food (Ottawa, CA)
Application Number:09/680,175
Patent Claims:1. An isolated nucleic acid that hybridizes under stringent conditions with a nucleotide sequence or a complement thereof selected from the group consisting of: nucleotides 1 to about 1668 of SEQ ID NO:2 nucleotides 1 to about 1986 of SEQ ID NO:2 nucleotides 1 to about 1959 of SEQ ID NO:2; nucleotides about 208 to about 1986 of SEQ ID NO:2; nucleotides about 888 to about 1986 of SEQ ID NO:2; nucleotides about 1134 to about 1986 of SEQ ID NO:2; nucleotides about 1446 to about 1986 of SEQ ID NO:2; nucleotides about 1668 to about 1986 of SEQ ID NO:2; nucleotides about 1868 to about 1986 of SEQ ID NO:2; and nucleotides about 1668 to about 1868 of SEQ ID NO:2,

wherein said stringent conditions comprise hybridizing said nucleic acid to said nucleotide sequence in 4.times.SSC at 65.degree. C. followed by washing in 0.1.times.SSC at 65.degree. C. for an hour, wherein said isolated nucleic acid exhibits silk activity.

2. The isolated nucleic acid of claim 1 comprising nucleotides 1 to about 1959 of SEQ ID NO:2.

3. The isolated nucleic acid of claim 1 comprising nucleotides from about 208 to about 1986 of SEQ ID NO:2.

4. The isolated nucleic acid of claim 1 comprising nucleotides from about 888 to about 1986 of SEQ ID NO:2.

5. The isolated nucleic acid of claim 1 comprising nucleotides from about 1134 to about 1986 of SEQ ID NO:2.

6. The isolated nucleic acid of claim 1 comprising nucleotides from about 1442 to about 1986 of SEQ ID NO:2.

7. The isolated nucleic acid of claim 1 comprising nucleotides from about 1668 to about 1986 of SEQ ID NO:2.

8. The isolated nucleic acid of claim 1 comprising nucleotides from about 1668 to about 1868 of SEQ ID NO:2.

9. The isolated nucleic acid of claim 1 comprising nucleotides 1 to about 1986 of SEQ ID NO:2.

10. The isolated nucleic acid of claim 1 comprising nucleotides 1 to about 1668 of SEQ ID NO:2.

11. A chimeric construct comprising the nucleic acid of claim 1 in operative association with a coding sequence of interest.

12. The chimeric construct of claim 11 further comprising a heterologous regulatory element in operative association with said nucleic acid and said coding sequence of interest.

13. A vector comprising the chimeric construct of claim 11.

14. The chimeric gene construct of claim 11 wherein said nucleic acid comprises nucleotides from about 208 to about 1986 of SEQ ID NO:2 in operative association with RPLC4.

15. A vector comprising the chimeric construct of claim 12.

16. A transgenic plant cell comprising the vector of claim 13.

17. A transgenic seed comprising the vector of claim 13.

18. A transgenic plant comprising the vector of claim 13.

19. A method of producing a plant expressing a coding sequence of interest within silk or pistil tissue comprising: i) transforming a plant with a vector of claim 13 to produce a transformed plant; and ii) growing said transformed plant.

20. The chimeric construct of claim 14, further comprising an intron in operative association with said nucleic acid.

21. A transgenic plant cell comprising vector of claim 15.

22. A transgenic seed comprising the vector of claim 15.

23. A transgenic plant comprising the vector of claim 15.

24. The method of claim 19, wherein the step of transforming further comprises as step of confirming the presence of said coding sequence in said transformed plant.

Details for Patent 6,515,204

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Schering INTRON A interferon alfa-2b VIAL 103132 001 1986-06-04 ➤ Sign Up Her Majesty the Queen in right of Canada, as represented by The Minister of Agriculture and Agri-Food (Ottawa, CA) 2019-10-05 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 002 1986-06-04 ➤ Sign Up Her Majesty the Queen in right of Canada, as represented by The Minister of Agriculture and Agri-Food (Ottawa, CA) 2019-10-05 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 003 1986-06-04 ➤ Sign Up Her Majesty the Queen in right of Canada, as represented by The Minister of Agriculture and Agri-Food (Ottawa, CA) 2019-10-05 RX search
Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source

Subscribe to access the full database, or try a Free Trial

International Patent Family for US Patent 6,515,204

Country Patent Number Publication Date
Canada 2321269 Apr 05, 2001
Canada 2321269 Jun 26, 2007
Country Patent Number Publication Date

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Deloitte
Julphar
Cipla
QuintilesIMS
Teva
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.